Tislelizumab-related enteritis successfully treated with adalimumab:A case report  

作　　者：Na Chen Min-Jia Qian Ru-Hui Zhang Qi-Qi Gao Chao-Chao He Ya-Ke Yao Jian-Ying Zhou Hua Zhou 

机构地区：[1]Department of Clinical Pharmacy,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China [2]Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China [3]Department of Critical Care Medicine,Zhuji People’s Hospital,Shaoxing 311800,Zhejiang Province,China [4]Department of Pathology,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China [5]Department of Pharmacy,Yiwu Central Hospital,Jinhua 322000,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2022年第28期10186-10192,共7页世界临床病例杂志

摘　　要：BACKGROUND With programmed death-1(PD-1) inhibitors becoming the standard treatment for lung cancer,PD-1-related adverse reactions and treatment have gradually become prominent.CASE SUMMARY First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles.The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms,abdominal computed tomography and colonoscopy improved,significant diarrhea was not occurred.CONCLUSION Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.

关 键 词：Tislelizumab ADALIMUMAB ENTERITIS Case report 

分 类 号：R734.2[医药卫生—肿瘤] R574[医药卫生—临床医学]